From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Direct-to-Consumer Advertising of Prescription Drugs

In the past decade, drug companies have quadrupled expenditures on ads aimed at consumers.

Direct-to-consumer (DTC) advertising of prescription drugs is perhaps the most controversial form of pharmaceutical marketing in the U.S. Researchers from Pittsburgh gathered information on DTC advertising during the past decade.

Key findings were as follows:

  • Total spending on DTC advertising in the U.S. increased from about $1 billion in 1996 to $4 billion in 2005; DTC advertising represented about 14% of drug company promotional expenditures in 2005.
  • DTC advertising consumed about one third of the total marketing budgets for proton-pump inhibitors, statins, and erythropoietin in 2005. The five single drugs with the highest expenditures for DTC advertising were Nexium, Lunesta, Vytorin, Crestor, and Advair.
  • From 2002 to 2006, DTC advertising was the target of one third to one half of letters sent by the FDA to drug companies regarding violations in regulations on drug promotion. Most citations were for DTC advertising that minimized risks or exaggerated effectiveness.
  • The authors suggest that the level of FDA staffing dedicated to review of DTC advertising has not kept pace with the recent increase in DTC advertising.

Comment: Drug companies maintain that DTC advertising benefits patients because it increases awareness of drugs that might otherwise be underprescribed. In contrast, many clinicians believe that harmful effects (e.g., stimulating patient demand for unnecessary medications) outweigh any putative benefits. In my view, the big problem — both in DTC advertising and in drug promotion to physicians — is the manipulation of information in ways that subtly overstate the drug’s benefits, indications, and target populations.

Allan S. Brett, MD

Published in Journal Watch General Medicine August 15, 2007

Citation(s):

Donohue JM et al. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med 2007 Aug 16; 357:673-81.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2007. Massachusetts Medical Society. All rights reserved.